Advances in coil technology and the development of tailored sequences have made 3T a versatile alternative to 1.5T. But it will be a long time until it displaces 1.5T as the workhorse of MR.
Advances in coil technology and the development of tailored sequences have made 3T a versatile alternative to 1.5T. But it will be a long time until it displaces 1.5T as the workhorse of MR.
New 3T scanners account for slightly more than 10% of the $1.4 billion spent annually on new MR scanners in the U.S. In terms of unit numbers, the piece of the MR pie consumed by 3T is even smaller, as 1.5T scanners go for hundreds of thousands of dollars less than the higher field units. Both percentages-revenue and actual numbers-may tail off in the future, unless workflow issues and reimbursement pressures are resolved.
Ensuring 3T's place in the market is the guarantee it affords buyers against future obsolescence. Migrating established applications from 1.5T to 3T supports present-day exams, while providing the power to handle signal-intensive scans of the future.
Philips took this idea to the next level with its new Achieva XR, which can be configured to run at 1.5T and later be upgraded onsite to 3T. The 1.5T configuration costs more than a conventional 1.5T scanner but substantially less than a 3T.
There is something to be said, however, for jumping directly into 3T. Those willing to commit can skip the costs of upgrading and go directly to Philips' Achieva 3T X-series, GE's Signa HDx 3.0T, or Siemens' Trio. They will have an added choice when Toshiba commercializes its 3T scanner, shown as a work-in-progress at RSNA 2006.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.